Loading...

NeuroMetrix

DB:NLZD
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NLZD
DB
$8M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
  • NeuroMetrix has significant price volatility in the past 3 months.
NLZD Share Price and Events
7 Day Returns
-3.5%
DB:NLZD
3.6%
DE Medical Equipment
2.1%
DE Market
1 Year Returns
-18.4%
DB:NLZD
20.7%
DE Medical Equipment
-7.6%
DE Market
NLZD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NeuroMetrix (NLZD) -3.5% 14.7% 50.4% -18.4% -91.7% -98.3%
DE Medical Equipment 3.6% 5.2% 9% 20.7% 89.9% 188.9%
DE Market 2.1% 3.6% 8.1% -7.6% 9.8% 12.4%
1 Year Return vs Industry and Market
  • NLZD underperformed the Medical Equipment industry which returned 20.7% over the past year.
  • NLZD underperformed the Market in Germany which returned -7.6% over the past year.
Price Volatility
NLZD
Industry
5yr Volatility vs Market
Related Companies

NLZD Value

 Is NeuroMetrix undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of NeuroMetrix to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for NeuroMetrix.

DB:NLZD Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.9%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:NLZD
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.93
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.932 (1 + (1- 21%) (0%))
0.955
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.95
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.955 * 5.96%)
5.92%

Discounted Cash Flow Calculation for DB:NLZD using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for NeuroMetrix is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:NLZD DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.92%)
2019 -1.15 Analyst x1 -1.09
2020 4.49 Analyst x1 4.00
2021 8.58 Analyst x1 7.22
2022 11.73 Analyst x1 9.32
2023 13.37 Analyst x1 10.03
2024 14.61 Est @ 9.25% 10.35
2025 15.56 Est @ 6.54% 10.41
2026 16.29 Est @ 4.65% 10.28
2027 16.83 Est @ 3.32% 10.03
2028 17.23 Est @ 2.39% 9.70
Present value of next 10 years cash flows $80.25
DB:NLZD DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $17.23 × (1 + 0.23%) ÷ (5.92% – 0.23%)
$303.58
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $303.58 ÷ (1 + 5.92%)10
$170.85
DB:NLZD Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $80.25 + $170.85
$251.10
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $251.10 / 7.88
$31.86
DB:NLZD Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:NLZD represents 0.84464x of NasdaqCM:NURO
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.84464x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 31.86 x 0.84464
€26.91
Value per share (EUR) From above. €26.91
Current discount Discount to share price of €0.95
= -1 x (€0.95 - €26.91) / €26.91
96.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price NeuroMetrix is available for.
Intrinsic value
>50%
Share price is €0.95 vs Future cash flow value of €26.91
Current Discount Checks
For NeuroMetrix to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • NeuroMetrix's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • NeuroMetrix's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NeuroMetrix's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NeuroMetrix's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NLZD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $0.00
NasdaqCM:NURO Share Price ** NasdaqCM (2019-03-20) in USD $1.12
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 31.31x
Germany Market PE Ratio Median Figure of 423 Publicly-Listed Companies 18.91x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NeuroMetrix.

DB:NLZD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:NURO Share Price ÷ EPS (both in USD)

= 1.12 ÷ 0.00

337.15x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NeuroMetrix is overvalued based on earnings compared to the DE Medical Equipment industry average.
  • NeuroMetrix is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does NeuroMetrix's expected growth come at a high price?
Raw Data
DB:NLZD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 337.15x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
58.5%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.82x
Germany Market PEG Ratio Median Figure of 276 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

DB:NLZD PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 337.15x ÷ 58.5%

5.76x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NeuroMetrix is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on NeuroMetrix's assets?
Raw Data
DB:NLZD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.83
NasdaqCM:NURO Share Price * NasdaqCM (2019-03-20) in USD $1.12
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.33x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.79x
DB:NLZD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:NURO Share Price ÷ Book Value per Share (both in USD)

= 1.12 ÷ 0.83

1.36x

* Primary Listing of NeuroMetrix.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NeuroMetrix is good value based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess NeuroMetrix's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. NeuroMetrix has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NLZD Future Performance

 How is NeuroMetrix expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
58.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NeuroMetrix expected to grow at an attractive rate?
  • NeuroMetrix's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • NeuroMetrix's earnings growth is expected to exceed the Germany market average.
  • NeuroMetrix's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:NLZD Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:NLZD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 58.5%
DB:NLZD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 19%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 11.9%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 5.9%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NLZD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NLZD Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 42 10 1
2022-12-31 35 7 1
2021-12-31 29 4 1
2020-12-31 24 0 1
2019-12-31 19 -6 1
DB:NLZD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 16 3 0
2018-09-30 17 0 0
2018-06-30 17 -3 -7
2018-03-31 18 -7 -11
2017-12-31 17 -13 -20
2017-09-30 16 -13 -20
2017-06-30 16 -14 -17
2017-03-31 14 -15 -38
2016-12-31 12 -15 -35
2016-09-30 11 -15 -43
2016-06-30 10 -15 -42
2016-03-31 8 -14 -23

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • NeuroMetrix's earnings are expected to grow significantly at over 20% yearly.
  • NeuroMetrix's revenue is expected to grow by 19% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NLZD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from NeuroMetrix Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NLZD Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.71 0.71 0.71 1.00
2022-12-31 0.49 0.49 0.49 1.00
2021-12-31 0.28 0.28 0.28 1.00
2020-12-31 0.02 0.02 0.02 1.00
2019-12-31 -0.41 -0.41 -0.41 1.00
DB:NLZD Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 0.00
2018-09-30 -0.01
2018-06-30 -1.65
2018-03-31 -3.72
2017-12-31 -11.60
2017-09-30 -15.64
2017-06-30 -19.02
2017-03-31 -52.72
2016-12-31 -58.21
2016-09-30 -80.27
2016-06-30 -89.86
2016-03-31 -57.29

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if NeuroMetrix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess NeuroMetrix's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NeuroMetrix has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NLZD Past Performance

  How has NeuroMetrix performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NeuroMetrix's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NeuroMetrix's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • NeuroMetrix has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • NeuroMetrix has become profitable in the last year making it difficult to compare the DE Medical Equipment industry average.
Earnings and Revenue History
NeuroMetrix's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NeuroMetrix Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NLZD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 16.09 0.02 15.17 4.51
2018-09-30 17.29 -0.05 15.78 4.28
2018-06-30 17.17 -7.48 16.61 3.94
2018-03-31 17.73 -11.29 17.40 3.20
2017-12-31 17.09 -19.73 17.11 2.83
2017-09-30 15.88 -19.67 16.59 2.95
2017-06-30 15.72 -17.23 16.54 3.31
2017-03-31 14.06 -37.94 16.50 3.56
2016-12-31 12.03 -34.76 16.31 3.81
2016-09-30 11.05 -42.99 16.15 3.88
2016-06-30 9.71 -42.28 15.38 3.62
2016-03-31 8.29 -23.09 14.24 3.47
2015-12-31 7.30 -21.07 13.41 3.22
2015-09-30 5.97 -12.94 12.33 2.99
2015-06-30 5.35 -11.20 10.83 2.99
2015-03-31 5.46 -11.57 9.69 3.48
2014-12-31 5.51 -10.72 8.28 3.44
2014-09-30 5.51 -11.52 7.04 3.25
2014-06-30 5.39 -10.77 6.79 3.04
2014-03-31 5.21 -7.76 6.82 2.49
2013-12-31 5.28 -8.79 7.64 2.80
2013-09-30 5.40 -6.96 7.64 3.29
2013-06-30 5.85 -8.85 8.65 3.53
2013-03-31 6.90 -9.51 9.75 3.64
2012-12-31 7.58 -10.01 11.17 2.84
2012-09-30 8.41 -10.55 11.06 3.81
2012-06-30 9.21 -10.37 11.47 3.66
2012-03-31 9.57 -10.04 11.27 3.57

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • NeuroMetrix has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • NeuroMetrix used its assets less efficiently than the DE Medical Equipment industry average last year based on Return on Assets.
  • It is difficult to establish if NeuroMetrix improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess NeuroMetrix's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NeuroMetrix has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NLZD Health

 How is NeuroMetrix's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NeuroMetrix's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NeuroMetrix is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • NeuroMetrix has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of NeuroMetrix's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • NeuroMetrix has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NeuroMetrix Company Filings, last reported 2 months ago.

DB:NLZD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 6.10 0.00 6.78
2018-09-30 8.86 0.00 7.53
2018-06-30 7.72 0.00 7.11
2018-03-31 6.82 0.00 6.10
2017-12-31 5.02 0.00 4.04
2017-09-30 4.52 0.00 3.97
2017-06-30 4.67 0.00 3.61
2017-03-31 7.85 0.00 6.90
2016-12-31 4.96 0.00 3.95
2016-09-30 7.71 0.00 7.57
2016-06-30 11.56 0.00 11.33
2016-03-31 8.85 0.00 8.74
2015-12-31 12.56 0.00 12.46
2015-09-30 8.49 0.00 9.12
2015-06-30 11.62 0.00 12.64
2015-03-31 1.68 0.00 6.40
2014-12-31 3.39 0.00 9.22
2014-09-30 6.20 0.00 11.69
2014-06-30 7.61 0.00 13.69
2014-03-31 6.05 0.00 7.58
2013-12-31 7.19 0.00 9.20
2013-09-30 5.81 0.00 7.84
2013-06-30 6.44 0.01 9.59
2013-03-31 6.90 0.01 6.89
2012-12-31 8.80 0.02 8.70
2012-09-30 10.59 0.02 10.93
2012-06-30 13.11 0.03 13.32
2012-03-31 15.87 0.03 15.21
  • NeuroMetrix has no debt.
  • NeuroMetrix had no debt 5 years ago.
  • NeuroMetrix has no debt, it does not need to be covered by operating cash flow.
  • NeuroMetrix has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess NeuroMetrix's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NeuroMetrix has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NLZD Dividends

 What is NeuroMetrix's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NeuroMetrix dividends.
If you bought €2,000 of NeuroMetrix shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NeuroMetrix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NeuroMetrix's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NLZD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 331 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:NLZD Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NeuroMetrix has not reported any payouts.
  • Unable to verify if NeuroMetrix's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NeuroMetrix's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NeuroMetrix has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess NeuroMetrix's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NeuroMetrix afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NeuroMetrix has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NLZD Management

 What is the CEO of NeuroMetrix's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Shai Gozani
COMPENSATION $478,211
AGE 53
TENURE AS CEO 22.2 years
CEO Bio

Dr. Shai N. Gozani, M.D., Ph.D., founded Neurometrix Inc. in 1996 and has been its President since 2002 and Chief Executive Officer since 1997 and its Secretary July 2008. He has been the Chairman of the Board at NeuroMetrix Inc. since June 1996. Dr. Gozani served as the President of NeuroMetrix Inc. from 1996 to 1998. He has been Director of Cyberkinetics Neurotechnology Systems Inc. since November 2007. He has published articles in the areas of basic and clinical neurophysiology, biomedical engineering and computational chemistry. He also received an M.D. from Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences at M.I.T. Dr. Gozani completed a neurophysiology research fellowship in the laboratory of Dr. Gerald Fischbach at Harvard Medical School. The Board has concluded that Dr. Gozani should serve as a Director because Dr. Gozani’s extensive knowledge of engineering and neurophysiology, combined with the unique understanding of technology and business he has gained as Founder and as a key executive, provides invaluable insight to NeuroMetrix, Inc.Board and to the entire organization. Dr. Gozani holds a B.S Degree in Computer Science, an M.S Degree in Biomedical Engineering and a Ph.D in Neurobiology from the University of California, Berkeley.

CEO Compensation
  • Shai's compensation has been consistent with company performance over the past year.
  • Shai's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the NeuroMetrix management team in years:

7
Average Tenure
57
Average Age
  • The average tenure for the NeuroMetrix management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Shai Gozani

TITLE
Founder
COMPENSATION
$478K
AGE
53
TENURE
22.2 yrs

Tom Higgins

TITLE
Senior VP
COMPENSATION
$357K
AGE
66
TENURE
9.5 yrs

Frank McGillin

TITLE
Senior VP & Chief Commercial Officer
COMPENSATION
$373K
AGE
57
TENURE
4.6 yrs

Michael MacDonald

TITLE
Senior VP of Commercial Operations & GM of Diagnostics

Xuan Kong

TITLE
Chief Data Scientist
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure and age of the NeuroMetrix board of directors in years:

8
Average Tenure
58
Average Age
  • The tenure for the NeuroMetrix board of directors is about average.
Board of Directors

Shai Gozani

TITLE
Founder
COMPENSATION
$478K
AGE
53
TENURE
22.8 yrs

Timothy Surgenor

TITLE
Independent Director
COMPENSATION
$51K
AGE
58
TENURE
9.9 yrs

Aaron Vinik

TITLE
Member of Scientific Advisory Board
TENURE
8 yrs

David Goodman

TITLE
Independent Director
COMPENSATION
$48K
AGE
63
TENURE
14.8 yrs

Nancy Katz

TITLE
Independent Director
COMPENSATION
$46K
AGE
58
TENURE
8.3 yrs

Andrew Boulton

TITLE
Member of the Scientific Advisory Board
TENURE
8 yrs

Neil Brooks

TITLE
Member of the Scientific Advisory Board
TENURE
8 yrs

Solomon Tesfaye

TITLE
Member of the Scientific Advisory Board
TENURE
8 yrs

Dan Ziegler

TITLE
Member of the Scientific Advisory Board
TENURE
8 yrs

Bruce Perkins

TITLE
Member of the Scientific Advisory Board
TENURE
8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
29. Oct 18 Sell Shai Gozani Individual 29. Oct 18 29. Oct 18 -3,760 €1.04 €-3,898
X
Management checks
We assess NeuroMetrix's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NeuroMetrix has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NLZD News

Simply Wall St News

NLZD Company Info

Description

NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.

Details
Name: NeuroMetrix, Inc.
NLZD
Exchange: DB
Founded: 1996
$7,287,340
7,880,463
Website: http://www.neurometrix.com
Address: NeuroMetrix, Inc.
1000 Winter Street,
Waltham,
Massachusetts, 02451,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM NURO Common Stock Nasdaq Capital Market US USD 22. Jul 2004
DB NLZD Common Stock Deutsche Boerse AG DE EUR 22. Jul 2004
DB A2DYWU COM USD0.0001(POST REV SPLT) Deutsche Boerse AG DE USD 20. Mar 2019
Number of employees
Current staff
Staff numbers
42
NeuroMetrix employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/20 21:31
End of day share price update: 2019/03/20 00:00
Last estimates confirmation: 2019/01/25
Last earnings filing: 2019/01/24
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.